Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)
Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)
Sponsor: Eli Lilly and Company
Listed as NCT00191282, this PHASE4 trial focuses on Acute Myocardial Infarction and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Eli Lilly and Company, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Oct 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Beirut, Lebanon , Brasov, Romania , Budapest, Hungary , Dresden, Germany , Istanbul, Turkey (Türkiye) , Jerusalem, Israel , Liverpool, United Kingdom , Maribor, Slovenia , New Delhi, India and 7 more locations